Medivir Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Medivir (STO:MVIR) Full Year 2024 Results

Key Financial Results

• Net loss: kr123.3m (loss widened by 38% from FY 2023).
• kr1.08 loss per share.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Medivir Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 50%. Earnings per share (EPS) missed analyst estimates by 29%.

Looking ahead, revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are down 6.1% from a week ago.

Risk Analysis

Before you take the next step you should know about the 4 warning signs for Medivir (2 are significant!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.